$2.2 Billion is the total value of Rock Springs Capital Management LP's 145 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PRAH | PRA HEALTH SCIENCES INC | $43,486,000 | +19.6% | 477,500 | 0.0% | 1.97% | +17.6% | |
| RDUS | RADIUS HEALTH INC | $29,959,000 | -17.6% | 943,000 | 0.0% | 1.36% | -19.0% | |
| PEN | PENUMBRA INC | $29,218,000 | +4.2% | 310,500 | 0.0% | 1.33% | +2.5% | |
| GILD | GILEAD SCIENCES INC | $22,452,000 | -11.6% | 313,400 | 0.0% | 1.02% | -13.0% | |
| EW | EDWARDS LIFESCIENCES CORP | $21,415,000 | +3.1% | 190,001 | 0.0% | 0.97% | +1.5% | |
| TMO | THERMO FISHER SCIENTIFIC INC | $20,887,000 | +0.4% | 110,000 | 0.0% | 0.95% | -1.2% | |
| AVXS | AVEXIS INC | $19,367,000 | +14.4% | 175,000 | 0.0% | 0.88% | +12.5% | |
| MDCO | MEDICINES CO | $18,865,000 | -26.2% | 690,000 | 0.0% | 0.86% | -27.4% | |
| BIIB | BIOGEN INC | $16,884,000 | +1.7% | 53,000 | 0.0% | 0.77% | 0.0% | |
| JAZZ | JAZZ PHARMACEUTICALS PLC | $16,656,000 | -7.9% | 123,700 | 0.0% | 0.76% | -9.5% | |
| BOLD | AUDENTES THERAPEUTICS INC | $16,406,000 | +11.6% | 525,000 | 0.0% | 0.74% | +9.7% | |
| PTLA | PORTOLA PHARMACEUTICALS INC | $15,763,000 | -9.9% | 323,800 | 0.0% | 0.72% | -11.4% | |
| CLVS | CLOVIS ONCOLOGY INC | $15,742,000 | -17.5% | 231,500 | 0.0% | 0.71% | -18.9% | |
| FGEN | FIBROGEN INC | $15,405,000 | -11.9% | 325,000 | 0.0% | 0.70% | -13.4% | |
| BAX | BAXTER INTL INC | $14,867,000 | +3.0% | 230,000 | 0.0% | 0.68% | +1.4% | |
| FOLD | AMICUS THERAPEUTICS INC | $13,095,000 | -4.6% | 910,000 | 0.0% | 0.59% | -6.2% | |
| HLS | HEALTHSOUTH CORP | $13,094,000 | +6.6% | 265,000 | 0.0% | 0.59% | +4.8% | |
| NVTA | INVITAE CORP | $11,858,000 | -3.1% | 1,306,000 | 0.0% | 0.54% | -4.8% | |
| ASND | ASCENDIS PHARMA A Ssponsored adr | $11,217,000 | +10.5% | 280,000 | 0.0% | 0.51% | +8.8% | |
| XENT | INTERSECT ENT INC | $11,178,000 | +4.0% | 345,000 | 0.0% | 0.51% | +2.2% | |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11,146,000 | -4.2% | 125,000 | 0.0% | 0.51% | -5.8% | |
| AIMT | AIMMUNE THERAPEUTICS INC | $11,081,000 | +52.6% | 293,000 | 0.0% | 0.50% | +50.1% | |
| CO | CHINA CORD BLOOD CORP | $8,756,000 | -10.5% | 880,000 | 0.0% | 0.40% | -12.0% | |
| RTRX | RETROPHIN INC | $8,428,000 | -15.3% | 400,000 | 0.0% | 0.38% | -16.8% | |
| OBSV | OBSEVA SA | $8,198,000 | +19.9% | 840,000 | 0.0% | 0.37% | +18.1% | |
| PRTK | PARATEK PHARMACEUTICALS INC | $8,055,000 | -28.7% | 450,000 | 0.0% | 0.36% | -29.9% | |
| RTIX | RTI SURGICAL INC | $7,995,000 | -9.9% | 1,950,000 | 0.0% | 0.36% | -11.2% | |
| RARE | ULTRAGENYX PHARMACEUTICAL IN | $7,560,000 | -12.9% | 163,000 | 0.0% | 0.34% | -14.2% | |
| ARNA | ARENA PHARMACEUTICALS INC | $7,304,000 | +33.2% | 215,000 | 0.0% | 0.33% | +30.8% | |
| SGEN | SEATTLE GENETICS INC | $6,688,000 | -1.7% | 125,000 | 0.0% | 0.30% | -3.5% | |
| BHVN | BIOHAVEN PHARMACTL HLDG CO L | $6,583,000 | -27.8% | 244,000 | 0.0% | 0.30% | -29.0% | |
| CMTA | CLEMENTIA PHARMACEUTICALS IN | $6,548,000 | +12.4% | 345,000 | 0.0% | 0.30% | +10.4% | |
| CLSD | CLEARSIDE BIOMEDICAL INC | $6,545,000 | -19.9% | 935,000 | 0.0% | 0.30% | -21.2% | |
| STE | STERIS PLC | $6,473,000 | -1.1% | 74,000 | 0.0% | 0.29% | -2.6% | |
| TTPH | TETRAPHASE PHARMACEUTICALS I | $5,985,000 | -7.9% | 950,000 | 0.0% | 0.27% | -9.3% | |
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $5,903,000 | +26.7% | 150,000 | 0.0% | 0.27% | +24.7% | |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $5,845,000 | -18.4% | 875,000 | 0.0% | 0.26% | -19.9% | |
| EXEL | EXELIXIS INC | $5,320,000 | +25.5% | 175,000 | 0.0% | 0.24% | +23.0% | |
| RARX | RA PHARMACEUTICALS INC | $5,100,000 | -41.8% | 600,000 | 0.0% | 0.23% | -42.8% | |
| MEDICINES COnote 2.750% 7/1 | $4,597,000 | -13.0% | 5,000,000 | 0.0% | 0.21% | -14.3% | ||
| CRVS | CORVUS PHARMACEUTICALS INC | $4,378,000 | -35.0% | 422,600 | 0.0% | 0.20% | -36.0% | |
| MGNX | MACROGENICS INC | $4,275,000 | +2.8% | 225,000 | 0.0% | 0.19% | +1.0% | |
| CBAY | CYMABAY THERAPEUTICS INC | $4,140,000 | +14.1% | 450,000 | 0.0% | 0.19% | +12.6% | |
| EGALET CORPnote 5.500% 4/0 | $3,754,000 | -7.3% | 7,800,000 | 0.0% | 0.17% | -9.1% | ||
| NABRIVA THERAPEUTICS PLC | $3,738,000 | -27.0% | 625,000 | 0.0% | 0.17% | -28.0% | ||
| MYOV | MYOVANT SCIENCES LTD | $3,730,000 | -18.3% | 295,100 | 0.0% | 0.17% | -19.9% | |
| MEDICINES COnote 2.500% 1/1 | $3,171,000 | -16.6% | 3,000,000 | 0.0% | 0.14% | -17.7% | ||
| ADRO | ADURO BIOTECH INC | $3,113,000 | -29.6% | 415,000 | 0.0% | 0.14% | -30.9% | |
| BMY | BRISTOL MYERS SQUIBB CO | $3,064,000 | -3.9% | 50,000 | 0.0% | 0.14% | -5.4% | |
| AGNPRA | ALLERGAN PLC5.5% cnv pfd a | $2,934,000 | -22.6% | 5,000 | 0.0% | 0.13% | -24.0% | |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $2,835,000 | +9.7% | 524,089 | 0.0% | 0.13% | +8.4% | |
| ITCI | INTRA CELLULAR THERAPIES INC | $2,715,000 | -8.2% | 187,500 | 0.0% | 0.12% | -10.2% | |
| MCRB | SERES THERAPEUTICS INC | $2,231,000 | -36.8% | 220,000 | 0.0% | 0.10% | -38.0% | |
| CGEN | COMPUGEN LTDord | $2,063,000 | -34.2% | 825,000 | 0.0% | 0.09% | -35.2% | |
| CDTX | CIDARA THERAPEUTICS INC | $2,040,000 | -16.0% | 300,000 | 0.0% | 0.09% | -17.0% | |
| CRME | CARDIOME PHARMA CORP | $1,860,000 | -27.6% | 1,200,000 | 0.0% | 0.08% | -28.8% | |
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $1,796,000 | -42.0% | 73,000 | 0.0% | 0.08% | -43.4% | |
| SCYX | SCYNEXIS INC | $1,763,000 | -3.8% | 760,000 | 0.0% | 0.08% | -5.9% | |
| ALPN | ALPINE IMMUNE SCIENCES INC | $1,680,000 | -3.4% | 150,000 | 0.0% | 0.08% | -5.0% | |
| THERAVANCE BIOPHARMA INCnote 3.250%11/0 | $1,645,000 | -10.8% | 1,500,000 | 0.0% | 0.08% | -11.8% | ||
| LIFE | ATYR PHARMA INC | $1,663,000 | -30.7% | 475,000 | 0.0% | 0.08% | -32.4% | |
| RADIUS HEALTH INCnote 3.000% 9/0 | $1,418,000 | -6.0% | 1,500,000 | 0.0% | 0.06% | -8.6% | ||
| WRIGHT MED GROUP INCnote 2.000% 2/1 | $1,031,000 | -5.1% | 1,000,000 | 0.0% | 0.05% | -6.0% | ||
| INFI | INFINITY PHARMACEUTICALS INC | $548,000 | +52.6% | 270,000 | 0.0% | 0.02% | +47.1% | |
| OREXQ | OREXIGEN THERAPEUTICS INC | $213,000 | -39.1% | 165,300 | 0.0% | 0.01% | -37.5% | |
| DARE | DARE BIOSCIENCE INC | $135,000 | -30.8% | 62,500 | 0.0% | 0.01% | -33.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.